Fumagillin

Fumagillin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	23110-15-8
PubChem	5284447
DrugBank	DB04838
ChemSpider	4445360
KEGG	D04197

Fumagillin is a natural product originally isolated from the fungus Aspergillus fumigatus. It is a complex organic compound that has been studied for its potential antimicrobial and antiparasitic properties. Fumagillin is particularly noted for its activity against microsporidia, a group of spore-forming unicellular parasites that can cause disease in immunocompromised individuals.

Mechanism of Action

Fumagillin exerts its effects by inhibiting the enzyme methionine aminopeptidase 2 (MetAP2). This inhibition disrupts the protein synthesis in microsporidia, leading to their death. The specific targeting of MetAP2 makes fumagillin a valuable tool in the treatment of microsporidial infections.

Medical Uses

Fumagillin has been used in the treatment of microsporidiosis, particularly in patients with HIV/AIDS who are more susceptible to these infections. It has also been explored for its potential use in treating intestinal microsporidiosis and other related conditions.

Side Effects

The use of fumagillin can be associated with several side effects, including gastrointestinal disturbances, hepatotoxicity, and bone marrow suppression. Patients receiving fumagillin should be monitored for these adverse effects, especially if they are on long-term therapy.

Research and Development

Research is ongoing to develop fumagillin analogs with improved efficacy and reduced toxicity. These efforts aim to enhance the therapeutic potential of fumagillin while minimizing its side effects.

See Also

• Antimicrobial agents
• Microsporidiosis
• Aspergillus fumigatus

External Links

• DrugBank: Fumagillin
• PubChem: Fumagillin

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology

• 
  Fumagillin